Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (NYSE: BDX) is a global leader in medical technology driving advancements in healthcare through innovative devices, diagnostic solutions, and clinical systems. This page provides real-time updates on BD's latest developments, offering investors and professionals a centralized hub for tracking corporate announcements and industry impact.
Access authoritative information including earnings reports, regulatory milestones, product innovations, and strategic partnerships. Our curated news collection helps stakeholders monitor BD's contributions to medication management, diagnostic testing, and surgical care across 190+ countries.
Key updates cover BD Medical safety-engineered products, BD Life Sciences diagnostic platforms, and BD Interventional surgical technologies. Stay informed about developments in smart medication systems, infectious disease testing, and minimally invasive procedures shaping modern healthcare.
Bookmark this page for ongoing insights into BD's operational updates, leadership changes, and R&D breakthroughs. Verify critical information directly through primary sources while maintaining awareness of market trends in the $600B+ medical technology sector.
BD (Becton, Dickinson and Company) has appointed William "Bill" Brown to its board of directors effective February 28, 2022. Brown, an experienced executive, is currently the executive chair of L3Harris Technologies with $18 billion in annual revenue. He previously served as chair and CEO of L3Harris from July 2019 to June 2021. BD's chairman, Tom Polen, expressed confidence in Brown's leadership skills to support the company's BD2025 strategy aimed at long-term stakeholder value. Having degrees in engineering and an MBA, Brown also holds several board positions.
BD (Becton, Dickinson and Company) will present virtually at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 9:50 a.m. ET. The event is accessible via a live webcast on the BD investor relations website, and a replay will be available afterward. BD, a leading global medical technology company, focuses on enhancing health care through innovative solutions. With a workforce of approximately 75,000, the company supports health care providers in improving safety and efficiency in patient care.
BD (Becton, Dickinson and Company) has appointed Shana Neal as the new chief people officer, effective April 4, 2022. Neal, who previously held various HR positions at BD from 2005 to 2018, will oversee global HR functions, including Talent Acquisition, Total Rewards, and Diversity initiatives. She replaces Betty Larson, who is transitioning to a new role in the healthcare sector. BD's CEO Tom Polen expressed confidence in Neal's leadership skills and industry knowledge as essential for advancing BD's 2025 strategy and enhancing stakeholder value.
BD (Becton, Dickinson and Company) announced that its diabetes care business, embecta, will spin off on April 1, 2022. To prepare investors, embecta will host a virtual Investor Event on March 7, 2022, starting at 8 a.m. Eastern Time. Presenters include CEO Dev Kurdikar and CFO Jake Elguicze, discussing the company's products, market opportunities, and financial strategies. A Q&A session will follow. More details and a link to the event are available on BD's investor webpage, with a replay accessible post-event.
BD (Becton, Dickinson and Company) reported Q1 FY2022 results with revenues of $4,995 million, down 6% from the previous year. Base revenues rose 8.1%, driven by strong performance in BD Medical, which grew 6% to $2,397 million. However, the BD Life Sciences segment saw a significant decline of 25% due to lower COVID-19 testing revenues. The company raised its FY2022 revenue guidance to $19.55-$19.75 billion and adjusted EPS to $12.80-$13.00. BD continues to focus on innovation, M&A, and ESG initiatives, while also navigating currency headwinds.
On February 1, 2022, BD (Becton, Dickinson and Company) announced its board of directors approved the spinoff of its diabetes care business, set to become Embecta Corp. The spinoff will take effect on April 1, 2022, with BD shareholders receiving one share of Embecta stock for every five shares of BD owned by March 22, 2022. The move aims to sharpen BD's focus on its core growth strategies and enhance Embecta's capacity for capital attraction and innovation in diabetes management. The IRS has deemed the transaction tax-free for U.S. federal income tax purposes.
BD (Becton, Dickinson and Company) has acquired Cytognos, a Spanish firm specializing in flow cytometry solutions for blood cancer diagnostics. This move enhances BD’s portfolio by integrating advanced assays for monitoring minimal residual disease (MRD) and improving cancer care. Cytognos brings over 25 years of expertise, complementing BD’s existing products and expanding its reach in chronic disease management. The acquisition, expected to be immaterial to BD's fiscal 2022 results, strengthens existing collaborations with the EuroFlow Consortium.
BD (Becton, Dickinson and Company) announced a peer-reviewed study in Obstetrics & Gynecology highlighting the effectiveness of molecular diagnostics in diagnosing vaginitis. The study found that clinician assessments missed 45.3% of positive cases and incorrectly identified 12.3% of negative cases. With vaginitis affecting 6 to 10 million women annually in the U.S., this study emphasizes the need for accurate diagnostic tools. The BD MAX™ Vaginal Panel Assay provides quicker and more accurate results, enhancing treatment decisions for patients.
FAQ
What is the current stock price of Becton Dickinson & Co (BDX)?
What is the market cap of Becton Dickinson & Co (BDX)?
